Muscle-type nicotinic acetylcholine receptor subunit alpha-1 (CHRNA1) (CHRNA1)

The Muscle-type nicotinic acetylcholine receptor subunit alpha-1 (CHRNA1) is a fundamental component of the pentameric ligand-gated ion channel located at the postsynaptic membrane of the neuromuscular junction (UniProt P02708). It serves as the primary binding site for the neurotransmitter acetylcholine, which, upon binding, triggers a conformational change that opens the channel to allow the influx of cations, primarily sodium, leading to muscle membrane depolarization and subsequent contraction (PubMed: 21840469). This subunit is a major therapeutic target for neuromuscular blocking agents used during surgical procedures to induce muscle relaxation, categorized into depolarizing agents like succinylcholine and non-depolarizing agents like rocuronium (StatPearls: NBK535383). Clinically, CHRNA1 is highly significant as the primary target of pathogenic autoantibodies in myasthenia gravis, an autoimmune disorder characterized by muscle weakness (PubMed: 30535111). Mutations in the CHRNA1 gene are also linked to various congenital myasthenic syndromes and lethal multiple pterygium syndrome, highlighting its essential role in human motor function (NCBI Gene: 1134). Pharmacological modulation of this receptor requires precise dosing to avoid prolonged paralysis or respiratory failure, making it a critical focus in anesthesiology and emergency medicine (StatPearls: NBK535383).

Other names

ACHRACHRNACMS1ACMS1BFCCMSSCCMSAcetylcholine receptor subunit alpha

Competitive antagonism of acetylcholine binding to prevent depolarization (non-depolarizing blockers) or persistent activation and depolarization of the motor endplate leading to desensitization (depolarizing blockers).